The combination of persistent equity dilution (24 offerings in 24 months), a meaningful ~8.3% discount to market, and $10.69/share of dilution per ADS suggests downward pressure on the stock near-term. Monitor for price stabilization post-offering and any clinical data catalysts (Phase 1b TNBC topline data expected early 2027). The warrants provide upside optionality only if the pipeline delivers, but the present dilution is certain.
Price Chart
Executive Summary
Kazia Therapeutics is raising approximately $37M in net proceeds through an underwritten public offering of 2,276,800 ADSs (at $15.50/ADS) and 303,200 pre-funded warrants, each bundled with Series A ($17.825 strike) and Series B ($19.375 strike) warrants tied to clinical milestones. The offering, priced at a ~8.3% discount to the last sale of $16.90, will fund expansion of paxalisib into new indications (HR+/HER2- breast cancer, colorectal cancer, early-stage high-risk TNBC) and continued TNBC enrollment. The significant immediate dilution ($10.69/ADS) and potential future dilution from up to 4.3M additional ADSs via warrant exercise are the primary concerns.
Key Facts
- Offering of 2,276,800 ADSs at $15.50/ADS and 303,200 pre-funded warrants at $15.4999, each with Series A and Series B warrants.
- Net proceeds to company ~$37M; total gross offering size ~$40M.
- Last reported ADS price on August 27, 2026 was $16.90 — a ~8.3% discount to the offering price.
- Immediate dilution of $10.69 per ADS for new investors ($15.50 offer price vs $4.81 as-adjusted net tangible book value per ADS).
- Shares outstanding will increase from ~6.48B to ~7.77B (actual) or up to ~9.93B (fully diluted assuming all warrants exercised).
- Series A Warrants (2.24M ADSs, $17.825 strike) expire on PFS milestone or 5yr; Series B Warrants (2.06M ADSs, $19.375 strike) similar.
- Proceeds primarily fund paxalisib clinical expansion into TNBC, HR+/HER2- breast cancer, colorectal cancer, and early-stage high-risk TNBC.
- 24 offering/registration filings by this company in the last 24 months, indicating persistent dilution.
- Short interest ~4.9% of estimated shares outstanding as of August 14, 2026.
- 60-day lock-up on officers, directors, and existing security holders from date of underwriting agreement.
Financial Impact
~$37M net proceeds from offering; immediate ~69% dilution of net tangible book value per ADS for new investors; potential additional ~$80M from warrant exercises contingent on clinical milestones.
Risk Factors
- Immediate and substantial dilution to existing shareholders.
- Warrant overhang (up to ~4.3M additional ADSs) may create persistent selling pressure if milestones approach or expire.
- Clinical trial risk — preliminary data from small N (6 patients) Phase 1b may not replicate in larger studies.
- No public market for warrants — holders may have limited liquidity.
- Foreign private issuer status reduces disclosure obligations compared to US domestic companies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-095303 |
| Document: 0001213900-26-095303-index-headers.html | 0001213900-26-095303 |
| Document: 0001213900-26-095303-index.html | 0001213900-26-095303 |
| Document: 0001213900-26-095303.txt | 0001213900-26-095303 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 23d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $7.63 (−17.69%) |
Sep 22, 2026 4w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $7.63 (−30.13%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $7.63 (−39.49%) |
Aug 31, 2026 7w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $7.63 (+39.59%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $7.63 (−44.59%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.63 (+44.59%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.63 (+44.59%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $7.63 (+43.81%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $7.63 (−43.81%) |
Jul 28, 2026 12w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $7.63 (−39.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers